.Globe Wellness Institution. Weight problems and also over weight. https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight (2024 ).
Non-Communicable Condition Danger Variable Cooperation. Worldwide styles in under a healthy weight as well as obesity from 1990 to 2022: a pooled evaluation of 3663 population-representative studies along with 222 thousand kids, teenagers, and adults. Lancet 403, 1027u00e2 $ “1050 (2024 ).
Articleu00c2.Google.com Scholaru00c2.Worldwide Worry Ailment Collaborators. Global, regional, as well as nationwide trouble of diabetic issues coming from 1990 to 2021, with forecasts of frequency to 2050: a systematic analysis for the International Trouble of Disease Research Study 2021. Lancet 402, 203u00e2 $ “234 (2023 ).
Articleu00c2.Google Scholaru00c2.Kovesdy, C. P., Furth, S. L.
& Zoccali, C & Globe Renal Time Guiding Board. Being overweight and also kidney health condition: hidden repercussions of the prevalent. Kidney Int.
91, 260u00e2 $ “262 (2017 ). Garofalo, C. et cetera.
A methodical customer review and also meta-analysis suggests weight problems predicts start of severe renal condition in the standard population. Kidney Int. 91, 1224u00e2 $ “1235 (2017 ).
Articleu00c2.Google.com Scholaru00c2.Jiang, Z. et cetera. Excessive weight and chronic kidney ailment.
Am. J. Physiol.
Endocrinol. Metab. 324, E24u00e2 $ “E41 (2023 ).
Articleu00c2.CASu00c2.Google.com Scholaru00c2.Venue, J. E., do Carmo, J. M., da Silva, A.
A., Wang, Z. & Hall, M. E.
Being overweight, renal dysfunction and also hypertension: mechanistic links. Nat. Rev.
Nephrol. 15, 367u00e2 $ “385 (2019 ). Articleu00c2.PubMed Centralu00c2.Google Scholaru00c2.Renal Condition: Improving Global End Results CKD The Office Group.
KDIGO 2024 Medical Practice Standard for the examination and control of persistent renal condition. Renal Int. 105, S117u00e2 $ “S314 (2024 ).
Articleu00c2.Google Scholaru00c2.Renal Condition: Improving Global End Results Diabetic Issues The Office Group. KDIGO 2022 Professional Method Tip for diabetes management in persistent renal condition. Kidney Int.
102, S1u00e2 $ “S127 (2022 ). Articleu00c2.Google Scholaru00c2.Oshima, M. et al.
Early modification in albuminuria with canagliflozin forecasts kidney and cardiovascular outcomes: a message hoc evaluation coming from the CREDENCE trial. J. Am.
Soc. Nephrol. 31, 2925u00e2 $ “2936 (2020 ).
Articleu00c2.CASu00c2.PubMed Centralu00c2.Google.com Scholaru00c2.de Zeeuw, D. et cetera. Proteinuria, an intended for renoprotection in individuals along with kind 2 diabetic nephropathy: lessons coming from RENAAL.
Renal Int. 65, 2309u00e2 $ “2320 (2004 ). Articleu00c2.Google.com Scholaru00c2.Heerspink, H.
J. et cetera. Is actually a decline in albuminuria related to kidney as well as cardio protection?
A post hoc analysis of the ALTITUDE test. Diabetes mellitus Obes. Metab.
18, 169u00e2 $ “177 (2016 ). Articleu00c2.CASu00c2.Google.com Scholaru00c2.Michos, E. D., Bakris, G.
L., Rodbard, H. W. & Tuttle, K.
R. Glucagon-like peptide-1 receptor agonists in diabetic person renal condition: a review of their renal and also heart security. Are actually.
J. Prev. Cardiol.
14, 100502 (2023 ). Articleu00c2.PubMed Centralu00c2.Google Scholaru00c2.Muskiet, M. H.
A. et cetera. GLP-1 and also the kidney: coming from anatomy to pharmacology and outcomes in diabetes mellitus.
Nat. Rev. Nephrol.
13, 605u00e2 $ “628 (2017 ). Articleu00c2.CASu00c2.Google Scholaru00c2.Marso, S. P.
et al. Semaglutide and also cardio outcomes in patients with kind 2 diabetic issues. N.
Engl. J. Med.
375, 1834u00e2 $ “1844 (2016 ). Articleu00c2.CASu00c2.Google Scholaru00c2.Lincoff, A. M.
et cetera. Semaglutide as well as heart end results in excessive weight without diabetic issues. N.
Engl. J. Medication.
389, 2221u00e2 $ “2232 (2023 ). Articleu00c2.CASu00c2.Google.com Scholaru00c2.Perkovic, V. et cetera.
Results of semaglutide on severe renal ailment in clients along with kind 2 diabetes. N. Engl.
J. Medication. 391, 109u00e2 $ “121 (2024 ).
Articleu00c2.CASu00c2.Google.com Scholaru00c2.Colhoun, H. M. et cetera.
Long-lasting kidney end results of semaglutide in weight problems and heart attack in the SELECT test. Nat. Med.
30, 2058u00e2 $ “2066 (2024 ). Articleu00c2.CASu00c2.PubMed Centralu00c2.Google Scholaru00c2.Heerspink, H. J.
L. et cetera. Results of semaglutide on albuminuria and kidney feature in people with over weight or being overweight along with or without kind 2 diabetes mellitus: prolegomenous evaluation from the measure 1, 2, and also 3 trials.
Diabetes Treatment 46, 801u00e2 $ “810 (2023 ). Articleu00c2.CASu00c2.PubMed Centralu00c2.Google.com Scholaru00c2.Medicine Man, A. M.
et al. Effect of the glucagon-like peptide-1 receptor agonists semaglutide as well as liraglutide on renal outcomes in clients along with type 2 diabetes: pooled evaluation of SUSTAIN 6 and also forerunner. Circulation 145, 575u00e2 $ “585 (2022 ).
Articleu00c2.CASu00c2.Google Scholaru00c2.Apperloo, E. M. et cetera.
Effect of semaglutide on kidney function around different degrees of baseline HbA1c, high blood pressure, physical body weight as well as albuminuria in SUSTAIN 6 as well as trailblazer 6. Nephrol. Dial.
Transplant. gfae150 (2024 ). Tuttle, K.
R. et cetera. Dulaglutide versus blood insulin glargine in patients along with kind 2 diabetes mellitus as well as moderate-to-severe severe kidney illness (AWARD-7): a multicentre, open-label, randomised trial.
Lancet Diabetic Issues Endocrinol. 6, 605u00e2 $ “617 (2018 ). Articleu00c2.CASu00c2.Google.com Scholaru00c2.Heerspink, H.
J. L. et al.
Modification in albuminuria as a surrogate endpoint for progression of renal health condition: a meta-analysis of procedure effects in randomised medical tests. Lancet Diabetic Issues Endocrinol. 7, 128u00e2 $ “139 (2019 ).
Articleu00c2.CASu00c2.Google Scholaru00c2.Mann, J. F. E.
et cetera. Results of semaglutide with as well as without coupled with SGLT2 inhibitor use in attendees with type 2 diabetes mellitus and severe kidney health condition in the circulation trial. Nat.
Medication. https://doi.org/10.1038/s41591-024-03133-0 (2024 ). Neuen, B.
L. et cetera. Cardiovascular, kidney and also security end results along with GLP-1 receptor agonists alone and in blend along with SGLT2 preventions in kind 2 diabetes: a methodical testimonial and meta-analysis.
Flow https://doi.org/10.1161/CIRCULATIONAHA.124.071689 (2024 ). Apperloo, E. M.
et al. Effectiveness as well as safety and security of SGLT2 inhibitors along with and also without glucagon-like peptide 1 receptor agonists: a SMART-C joint meta-analysis of randomised controlled trials. Lancet Diabetes Endocrinol.
12, 545u00e2 $ “557 (2024 ). Articleu00c2.CASu00c2.Google.com Scholaru00c2.Heerspink, H. J.
L. et al. Effects of tirzepatide versus blood insulin glargine on renal results in kind 2 diabetes mellitus in the SURPASS-4 test: post-hoc analysis of an open-label, randomised, phase 3 test.
Lancet Diabetes Mellitus Endocrinol. 10, 774u00e2 $ “785 (2022 ). Articleu00c2.CASu00c2.Google Scholaru00c2.Tuttle, K.
R. et cetera. Physical body weight and eGFR in the course of dulaglutide therapy in style 2 diabetic issues and also moderate-to-severe severe kidney health condition (AWARD-7).
Diabetic issues Obes. Metab. 21, 1493u00e2 $ “1497 (2019 ).
Articleu00c2.CASu00c2.Google.com Scholaru00c2.Heerspink, H. J. L.
et al. Effects of tirzepatide versus blood insulin glargine on cystatin c-based renal feature: a SURPASS-4 article hoc study. Diabetes Treatment 46, 1501u00e2 $ “1506 (2023 ).
Articleu00c2.CASu00c2.PubMed Centralu00c2.Google.com Scholaru00c2.Diabetes Care (American Diabetic issues Organization, accessed 1 September 2024) https://diabetesjournals.org/diabetes/issue/73/Supplement_1Li, K. et al. Effects of bariatric surgical operation on kidney function in obese patients: an organized analysis as well as meta analysis.
PLoS ONE 11, e0163907 (2016 ). Articleu00c2.PubMed Centralu00c2.Google Scholaru00c2.Bilha, S. C.
et cetera. The effects of bariatric surgery on renal results: an organized examine and meta-analysis. Obes.
Surg. 28, 3815u00e2 $ “3833 (2018 ). Articleu00c2.Google Scholaru00c2.Clerte, M.
et al. The measured glomerular filtration rate (mGFR) before and also 6 months after bariatric surgical procedure: a pilot study. Nephrol.
Ther. Thirteen, 160u00e2 $ “167 (2017 ). Articleu00c2.Google.com Scholaru00c2.Fawaz, S.
et cetera. Adiponectin decreases glomerular endothelial glycocalyx disturbance as well as recovers glomerular barrier feature in a computer mouse design of kind 2 diabetes mellitus. Diabetes mellitus 73, 964u00e2 $ “976 (2024 ).
Articleu00c2.CASu00c2.Google Scholaru00c2.Sasson, A. N. & Cherney, D.
Z. Kidney hyperfiltration related to diabetes mellitus and also weight problems in individual illness. World J.
Diabetes 3, 1u00e2 $ “6 (2012 ). Articleu00c2.PubMed Centralu00c2.Google.com Scholaru00c2.Chagnac, A. & Friedman, A.
N. Measuring albuminuria in people along with weight problems: difficulties of the urinary albumin-creatinine ratio. Kidney Medication.
6, 100804 (2024 ). Articleu00c2.PubMed Centralu00c2.Google.com Scholaru00c2.Wilding, J. P.
H. et cetera. Once-weekly semaglutide in adults with overweight or weight problems.
N. Engl. J.
Medication. 384, 989u00e2 $ “1002 (2021 ). Articleu00c2.CASu00c2.Google Scholaru00c2.Levey, A.
S. et cetera. An even more precise method to estimate glomerular filtering amount from lotion creatinine: a new forecast equation.
Modification of Diet Plan in Renal Disease Study Group. Ann. Trainee.
Medication. 130, 461u00e2 $ “470 (1999 ). Articleu00c2.CASu00c2.Google.com Scholaru00c2.Stevens, J.
et al. UHPLC-MS/MS technique for iohexol judgment in individual EDTA and also lithium-heparin plasma televisions, human pee as well as in goat- and also porker EDTA blood. Bioanalysis 12, 981u00e2 $ “990 (2020 ).
Articleu00c2.CASu00c2.Google.com Scholaru00c2.Tuttle, K. R. et cetera.
Efficacy as well as security of aldosterone synthase obstacle with and also without empagliflozin for persistent kidney condition: a randomised, handled, stage 2 trial. Lancet 403, 379u00e2 $ “390 (2024 ). Articleu00c2.CASu00c2.Google Scholaru00c2.de Zeeuw, D.
et al. Effectiveness of a novel prevention of vascular bond protein-1 in reducing albuminuria in individuals with diabetic kidney disease (CD): a randomised, placebo-controlled, period 2 test. Lancet Diabetic Issues Endocrinol.
6, 925u00e2 $ “933 (2018 ). Articleu00c2.Google Scholaru00c2.Heerspink, H. J.
L. et cetera. Zibotentan in combo with dapagliflozin compared to dapagliflozin in people along with persistent kidney disease (ZENITH-CKD): a multicentre, randomised, active-controlled, stage 2b, clinical test.
Lancet 402, 2004u00e2 $ “2017 (2023 ). Articleu00c2.CASu00c2.Google Scholaru00c2.Heerspink, H. J.
L. et cetera. Effect of avenciguat on albuminuria in people with CKD: pair of randomized placebo-controlled tests.
J. Am. Soc.
Nephrol. 25, 1227u00e2 $ “1239 (2024 ). Articleu00c2.Google Scholaru00c2.Heerspink, H.
J. L. et al.
Sparsentan in patients along with IgA nephropathy: a prespecified interim analysis due to a randomised, double-blind, active-controlled scientific trial. Lancet 401, 1584u00e2 $ “1594 (2023 ). Articleu00c2.CASu00c2.Google Scholaru00c2.